OSE Immunotherapeutics: Tedopi Selected for Presentation at ASCO 2026
OSE Immunotherapeutics announces the selection of its Phase 2 TEDOVA clinical trial results for an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Congress, to be held in Chicago from May 29 to June 2, 2026. This trial evaluates Tedopi® as a maintenance treatment for ovarian cancer.
The Phase 2 TEDOVA study, promoted by ARCAGY-GINECO, evaluates Tedopi® either as a monotherapy or in combination with pembrolizumab (Keytruda®), compared to standard care. The trial involves 185 patients with platinum-sensitive recurrent ovarian cancer, whose disease is controlled after platinum-based chemotherapy and who have previously received treatment with bevacizumab and a PARP inhibitor. The primary endpoint is progression-free survival (PFS) from maintenance treatment with Tedopi® in combination with a PD1 inhibitor after platinum-based chemotherapy. The study is also identified under the numbers GINECO-OV244b and ENGOT-ov58 (NCT04713514).
Presentation Details
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The oral presentation will be conducted by Professor Alexandra Leary, Deputy Head of the Oncology Medicine Department at Gustave Roussy, Chair of the GINECO group, and Principal Investigator of the TEDOVA study. The presentation is scheduled for May 30, 2026, from 3:06 PM to 3:12 PM CEST (8:06 AM to 8:12 AM CDT) in room E450, during the Gynecologic Cancer session, Ovarian Cancer sub-session (Abstract 5510).
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 1T2026
Risks mentioned
Taux de trésorerie et équivalents de trésorerie de 17,0 millions d'euros au 31 mars 2026 en baisse.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
